31.6 C
Vientiane
Sunday, June 8, 2025
spot_img
Home Blog Page 724

Coordinated regional strategy pays dividends

BEIJING, Feb. 27, 2025 /PRNewswire/ — A news report from China Daily: This year marks the 11th anniversary of the Beijing-Tianjin-Hebei coordinated development, a strategy that has reshaped the area.

A view of the Grand Canal CBD in the Beijing Municipal Administrative  Center. Wang Danfeng / for China Daily
A view of the Grand Canal CBD in the Beijing Municipal Administrative Center. Wang Danfeng / for China Daily

The strategy focuses on “one core and two wings”. One core refers to Beijing’s leading role in the coordinated development of the BeijingTianjinHebei region. Primary tasks include relieving Beijing of functions nonessential for the capital, optimizing its capital functions and addressing the “big city” problems. While advancing the relocation of functions nonessential for the capital, efforts are being made to promote reorganization, driving the wider development of the BeijingTianjinHebei region.

Over the past decade, the three places have not only pursued the relief of functions nonessential for the capital but advanced the harmonized growth of the “two wings to the capital city”: Beijing Municipal Administrative Center in Tongzhou district and the Xiong’an New Area in Hebei province. This has led to increased integration across key sectors, propelling the region toward a new era of collaborative progress.

By mutually reinforcing each other’s strengths, they have fostered a new atmosphere of coordinated development. In 2024, Beijing, Tianjin and Hebei achieved impressive GDP growth rates of 5.2 percent, 5.1 percent and 5.4 percent, respectively, all surpassing the national average.

The combined regional economic output soared to 11.5 trillion yuan ($1.58 trillion), underscoring the BeijingTianjinHebei region’s pivotal role as a driving force for high-quality national development.

This year, Beijing is poised to achieve breakthroughs in the implementation of the BeijingTianjinHebei development strategy, with a focus on accelerating the establishment of a modern capital metropolitan area, local officials said.

Key initiatives include the steadfast relief of functions nonessential for the capital, the orderly relocation of landmark projects from State-owned enterprises and government departments, and the enhancement of public services through the use of reclaimed spaces.

Furthermore, emphasis will be placed on upholding high standards and quality in the development of the Xiong’an New Area, particularly in critical areas such as basic education, healthcare, and vocational training innovation. Support will be extended to the advancement of the Zhongguancun Science Park in Xiong’an.

Beijing is set to expedite the high-quality development of its administrative center, advancing projects like a comprehensive transport hub, a national green development demonstration zone, and fostering innovative industrial growth in the Tongzhou-Wuqing-Langfang area.

Prioritizing coordinated innovation and industrial collaboration, efforts will be directed toward leveraging the Jingjinji National Center for Technology Innovation, which promotes the incubation and transformation of technological achievements across the BeijingTianjinHebei region.

Moreover, measures will be taken to enhance the quality and efficiency of advanced manufacturing clusters; establish the BeijingTianjinHebei intelligent connected new energy vehicle sci-tech eco-park; and boost the development of commercial aerospace, low-altitude industries, and synthetic biology, collaboratively nurturing new quality productive forces in the region.

To accelerate the construction of a modern capital metropolitan area, Beijing will enhance transport infrastructure by completing the tunnel section of the Beijing-Tangshan Intercity Railway and initiating a high-speed road linking Chengde city in Hebei with Pinggu district in Beijing. Moreover, the coverage of customized shuttle bus services for commuting in Beijing will be expanded.

Greater action will be taken to address air pollution during autumn and winter, and enhance joint management of cross-border rivers like the Chaobai and Yongding.

 

Alpro Foundation & Universiti Teknologi MARA: Addressing Malaysia’s Pharmaceutical Waste

KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ — Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or tossing them in regular trash—leading to contamination of the country’s vital water sources. With 99% of Malaysia’s domestic water supply coming from surface water, the presence of pharmaceutical residues in rivers and lakes poses serious risks to both human health and ecosystems.

(From left: Mindy Leong (Branding Manager of Alpro Pharmacy); Ostwin Paw ( CEO of Alpro Foundation); Professor Dato. Dr. Yamin bin Yassin (Rector of UiTM Negeri Sembilan); Prof. Dato Dr. Abu Bakar Abdul Majeed (Dean of the Faculty of Pharmacy in UiTM) )
(From left: Mindy Leong (Branding Manager of Alpro Pharmacy); Ostwin Paw ( CEO of Alpro Foundation); Professor Dato. Dr. Yamin bin Yassin (Rector of UiTM Negeri Sembilan); Prof. Dato Dr. Abu Bakar Abdul Majeed (Dean of the Faculty of Pharmacy in UiTM) )

A study by the Malaysian Ministry of Health found that only 15% of the population is aware of the correct methods for medication disposal. Meanwhile, researchers have detected traces of antibiotics, hormones, and painkillers in 35% of Malaysia’s waterways, threatening aquatic life and increasing antibiotic resistance risks. One of the biggest challenges remains accessibility—over 60% of rural households lack nearby pharmaceutical waste disposal facilities.

Recognizing the urgency of the issue, Alpro Foundation, the corporate social responsibility (CSR) arm of Alpro Pharmacy, Malaysia’s largest prescription pharmacy chain, is taking a monumental step toward environmental sustainability and public health by signing a Memorandum of Agreement (MoA) with Universiti Teknologi MARA (UiTM).

A Strategic Collaboration to Drive Change

The MoA encompasses four key initiatives designed to advance pharmaceutical waste management and public awareness:

  • Identifying, Categorizing, and Cost Estimation of Public Pharmaceutical Waste – Research will be conducted to classify and quantify pharmaceutical waste, assessing its environmental impact and economic implications.
  • Readiness Assessment of Stakeholders – This study will evaluate the preparedness of key stakeholders, including healthcare providers and the public, in implementing safe medication disposal practices across Malaysia.
  • Development of Educational Tools – UiTM and Alpro Pharmacy will create innovative educational materials designed for both pharmacy students and the general public to promote best practices in medication disposal.
  • Community-Based Awareness Campaigns – A grassroots approach will be employed to engage communities and drive behavioral change regarding pharmaceutical waste disposal.

A Nation-Wide Effort for a Sustainable Future

Since the launch of the Safe Medication Disposal Campaign in 2021, Alpro Foundation has made significant strides:

  • Partnered with over 800 schools and universities, reaching more than 300,000 students through school talks.
  • Collected more than 100,000 pledges nationwide from walk-in customers, committing to the safe disposal of unwanted medications.
  • Installed safe medication disposal bins in all 300 Alpro Pharmacy outlets nationwide, ensuring convenient and responsible disposal access for the public.
  • Reached over 50,000 families through safe medication disposal outreach programs, coloring competitions, medication safety competitions, and public education events.

In 2025, the Foundation aims to further expand its impact with the Faculty of Pharmacy, UiTM:

  • Enhancing Public Pharmaceutical Waste Identification & Management: Conducting large-scale data collection and classification of pharmaceutical waste to better understand its impact and advocate for improved disposal methods.
  • Educating Stakeholders on Readiness & Implementation: Engaging with over 350,000 individuals, including students and corporate stakeholders, to assess and enhance their preparedness for responsible pharmaceutical waste disposal.
  • Developing Educational Tools for Public & Pharmacy Students: Expanding outreach programs to 250,000 families through school talks, interactive workshops, and community engagement activities to improve public understanding of proper disposal techniques.
  • Strengthening Community-Based Awareness Campaigns: Establishing a dedicated awareness landmark, the “Little Red House”, outside Alpro’s headquarters, serving as both a disposal hub and an educational center for the public.

Protecting Malaysia’s Water Sources Through Responsible Disposal

“We have seen a growing number of healthcare providers and individuals recognizing the importance of safe medication disposal, but more needs to be done,” said Mr. Ostwin Paw, CEO of Alpro Foundation. “This MoA with UiTM represents a crucial step forward in protecting our environment, enhancing public education, and ensuring future generations inherit a healthier planet.”

Professor Amrahi Buang, President of the Malaysian Pharmacists Society, added, “Proper pharmaceutical waste management is no longer optional—it is a necessity. This partnership between Alpro Pharmacy and UiTM will help shape the future of safe medication disposal practices in Malaysia.”

En. Shahiri, Senior Principal Assistant Director of Program Perkhidmatan Farmasi, Ministry of Health, who is also leading My MediSafe initiative remarked, “The Ministry of Health strongly supports this initiative, as improper medication disposal poses risks to both public health and the environment. We look forward to working with all stakeholders to enhance awareness and facilitate responsible disposal solutions.”

Prof. Dato Dr Yamin Bin Yassin, Rector of UiTM Cawangan Negeri Sembilan, stated, “This collaboration with Alpro Pharmacy aligns with UiTM’s commitment to community engagement and sustainability. By combining research, education, and public awareness, we can drive meaningful change in pharmaceutical waste management.”

Alpro Foundation invites everyone to take part in this vital initiative. Dispose of your unwanted medications responsibly and contribute to a cleaner, safer Malaysia. For more details on the Alpro Safe Medication Disposal Campaign and to find a disposal bin near you, please visit https://www.alpropharmacy.com/services/medication-disposal-service/

About Alpro Pharmacy

With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio and Alpro Baby, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals.

Serving more than 3 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia.

For more information, please visit https://www.alpropharmacy.com.

MOVA Launches Stylish Smart Home Innovations: Z50 Ultra and X4 Pro Available March 2nd

The award-winning smart home appliance brand will introduce the MOVA Z50 Ultra and MOVA X4 Pro, redefining and enhancing the lives of modern, busy consumers and families with never-before-seen innovations and tech.

SINGAPORE, Feb. 27, 2025 /PRNewswire/ — MOVA, the globally recognized brand for innovative smart appliances, will add two new flagship products – the MOVA Z50 Ultra robot vacuum, and the MOVA X4 Pro wet and dry vacuum, to their extensive product lineup in Singapore on 2 March 2025 via Shopee and Lazada.

Having first made their debut at Consumer Electronics Show (CES) 2025, MOVA is set to sweep everyone off their feet with these new products boasting the best of their innovative technologies, with additional first-of-its-kind features that enhance smart home living for their users.


MOVA Z50 ULTRA – Game-Changing Tech for Smarter, Faster and Hands-Free Cleaning

Get the best of MOVA’s tech all in one robot vacuum! The new MOVA Z50 Ultra possesses stronger cleaning power with the integration of these unique MOVA innovations:

  • MOVA’s First Thermostatic HydroSync™ Mopping set at 36°C, the optimal temperature to dissolve stains, allows the Z50 Ultra to clean itself using water during mopping and enhances its cleaning effectiveness without damaging floors;
  • MOVA’s First D-Shaped Track-type mop design that covers more ground while cleaning, delivering a deep clean with less effort;
  • Real-time mop-fluffing engine that maintains optimal dirt absorption capacity while covering a larger area, improving cleaning performance up by 133%, compared to traditional mop pads; 
  • Triple-Intelligence AI Sensing that allows the Z50 Ultra to avoid obstacles and detect different dirt types, enabling it to adapt to different cleaning scenarios, based on household types and areas.


Tiny but mighty, the MOVA Z50 Ultra possesses a powerful suction of 19,000Pa and dual rotary mops that allow it to clean even the tightest of edges and corners with ease.

Thanks to its base station that allows it to self-clean, along with triple anti-tangle features, the MOVA Z50 Ultra is pet-friendly and hands-free with little need for maintenance. Users can rest easy as the “trusted helper” puts in the work to keep their house spick and span.

MOVA X4 PRO – Turn The Heat Up On Any Mess With The Award-Winning X4 Pro

Accompanying this latest launch is the MOVA X4 Pro, a cordless wet and dry vacuum, that makes use of MOVA’s pioneering technology for more effective and convenient cleaning. This smart appliance equips users with exceptional, all-rounded cleaning efficiency through a combination of groundbreaking features:

MOVA’s First SpotHeat™ Spray Cleaning Uses 80°C Hot Water for Ten Times the Stain Removal Power, Effortlessly Breaking Down Even the Toughest Stains!

  • 180° Lie-Flat Reach that allows users to easily access low gaps and hard-to-reach areas;
  • 20,000Pa suction power that efficiently tackles wet and dry messes;
  • Dual-edge cleaning with the in-built brush, leaving no gaps uncleaned when cleaning against walls; and
  • A Lift-Free & Push-In design for its base station for effortless docking and self-cleaning, delivering a seamless cleaning session from start to finish.

Weighing only 1.1kg with two mini wheels and a 60° swivel for smooth movement around corners, the MOVA X4 Pro is easy to handle and manoeuvre. Topped off with an LED-lit brush head that automatically activates to reveal pet hair and fine dust, the MOVA X4 Pro’s precise cleaning capabilities are a notch above the rest in ensuring that your floors remain pristine.


Plus, with 100°C Deep Brush Washing that effectively dissolves grime on the brush and MOVA’s Tangle-Free™ Solution that uses a scraper to effectively extract hair and expel dirt, the MOVA X4 Pro is able to keep itself clean while enhancing its durability for long-lasting use.

As a testament to MOVA’s groundbreaking innovations, the MOVA X4 Pro took home two awards – the CES Innovation Award 2025 from House Digest, and the CES Picks Award 2025 from Twice at CES 2025!

Transforming Day-to-Day Lives With MOVA’s Smart Cleaning Innovations

MOVA’s commitment to innovation and style has garnered global recognition, having successfully entered the markets of over 30 countries and regions worldwide with a stellar lineup of products, ranging from home appliances, including robot vacuums, to personal care products, such as hairdryers.

With “Premium, Innovative, Stylish” as the core keywords of the brand’s DNA, MOVA aims to continue innovating and presenting groundbreaking technologies and products to consumers, with the goal of redefining the future of smart home living.

The MOVA Z50 Ultra and MOVA X4 Pro will be available from 2 March 2025 at 8pm via Shopee and Lazada at special launch prices of $1,499 (U.P. S$2,089) for the first 50 purchases and $749 (U.P. S$1,199) for the first 20 purchases respectively, with the MOVA Z50 Ultra available for pre-order only.

About MOVA

MOVA is a global innovative smart appliance brand that advocates “leading innovation, connecting technology with daily life.” It is dedicated to creating new intelligent living spaces for families worldwide through continuous technological breakthroughs, exploring future home living styles. For more information, please visit http://global.mova-tech.com.

Follow MOVA Singapore:

Facebook: https://www.facebook.com/MovaSG

Instagram: @mova.sg

Revolutionizing All-on-X: Medit’s Game-Changing Workflow Will Launch Soon

SEOUL, South Korea and NEWPORT BEACH, Calif., Feb. 27, 2025 /PRNewswire/ — Medit (www.medit.com), a global leader in digital dentistry, is set to revolutionize the digital All-on-X workflow, making it more accessible, efficient, and intuitive for Medit scanner users.

Medit SmartX
Medit SmartX

Starting in March, Medit will introduce the Medit All-on-X Workflow, Medit SmartX, enabling users to effortlessly scan to verify implant positions and initiate the workflow without the need for complex procedures or additional scanner purchases. With the flexibility to work with scanbodies of their choice, users can seamlessly integrate the workflow into their existing setup without being restricted to specific components.

A Preview of Medit SmartX Advantages

1.    Designed for All Users
Clear, easy-to-follow protocol ensure a seamless adoption process for both new and experienced users.

2.    Streamlined Workflow
Enhance efficiency with real-time automatic library alignment, providing an intuitive process and simplifying the scanning workflow.

3.    Optimized Scanning Data
Redefining scan alignment and capture techniques to deliver exceptionally precise and detailed scan results.

4.    No Additional Scanner
Medit scanner users can instantly initiate the workflow using their existing Medit scanner models (available for Medit i900, Medit i700 Wireless, Medit i700, and Medit i600).

Medit disrupted the market in 2018 with its first intraoral scanner, offering dentists a high-precision, user-friendly option at a significantly lower cost than competitors. Building on this success, Medit introduced the best-selling i700 in 2021, followed by the i700 Wireless and i600 in 2022, and the i900 in 2024, providing a comprehensive range of scanners for all types of dental practices.

With innovative solutions never before seen in the market, Medit continues to redefine the standards of digital dentistry. Stay tuned for the official launch of the Medit SmartX on March 18th.

About Medit

MEDIT is a global provider of 3D intraoral scanners and an all-in-one digital dentistry platform, based on its own patented state-of-the-art technology. The company also develops innovative software for digital dentistry, supporting collaborative workflows between dental clinics and labs. MEDIT has been headquartered in Seoul, South Korea since its inception in 2000. The company also has representatives located in the Americas and Europe and boasts a global network of distributors in over 100 countries. For detailed information about MEDIT products and software, please visit MEDIT official website(www.medit.com). For other various content, please refer to MEDIT official YouTube(youtube.com/user/meditcompany) and other social media channels (instagram.com/meditcompany/).

Ming Tak Finance Gold Trading Competition: Champion Achieves 1049% Growth, with Over HKD 500,000 in Total Prizes

Reliable and Professional: Ming Tak Finance Offers Low Spreads and Stable Platforms to Support Traders in Achieving Consistent Profits


HONG KONG SAR – Media OutReach Newswire – 27 February 2025 – Ming Tak Finances Gold Trading Competition has successfully concluded its preliminary round, with participants showcasing exceptional trading skills and strategies in a highly competitive environment. The competition highlights the advantages of Ming Tak Finances ultra-low spread of just 0.15 USD and its stable trading platform, confirming the substantial profit potential in the gold trading market. As a member of the Hong Kong Gold & Silver Exchange (Member No. 194), Ming Tak Finance provides physical gold and margin trading services, backed by the Hong Kong Customs Precious Metals Trader License (Registration No. A-B-23-07-00744). Ming Tak Finance has also received several prestigious industry awards, including the 2024 Excellence in Precious Metals Trading Platform Service Award from Capital Platform, and the Best Precious Metals Trading Platform award from iMoney Wealth Magazine.

Ming Tak Finance Gold Trading Competition

During the preliminary round, the champion achieved an incredible 1049% growth, with the total prize pool exceeding HKD 500,000, further solidifying the profitability of gold trading on a reliable platform.

Champion: Chu Tak Shing (1049%) – Aggressive Strategy and Ming Tak Finances Stable Platform Lead to Victory

Chu Tak Shing won the championship with a remarkable 1049% growth rate. He shared, I used an aggressive short-term strategy, taking full advantage of Ming Tak Finances low spread and reliable pricing system to achieve impressive returns in a volatile market.” Chu highlighted Ming Tak Finances membership in the Hong Kong Gold & Silver Exchange Society, which provides a transparent and trusted trading environment, allowing him to stay stable and achieve excellent results even during market fluctuations. His success was driven by his precise strategy combined with the professional platform offered by Ming Tak Finance, which enabled him to achieve tenfold profits and secure the championship.

Runner-up: Nam Sai Cheong Alex (849%) – Stable Strategy and Ming Tak Finances Reliable Pricing System

Nam Sai Cheong Alex secured second place with an 849% growth rate. He commented, Gold markets are highly volatile, but Ming Tak Finances low spread and stable pricing system helped me focus on my strategy and seize profit opportunities.” Nam emphasized that Ming Tak Finances membership with the Hong Kong Gold & Silver Exchange Society gave him the confidence to rely on their platform for consistent profits in a competitive market.

Third Place: Chan Chun Choi (823%) – Balancing Long-Term Stability with Risk Management

Chan Chun Choi claimed third place with an 823% growth rate. He noted, I prefer a stable long-term approach, and Ming Tak Finances transparent trading environment and low spread allowed me to manage risk effectively and achieve steady growth.” As a licensed broker and member of the Hong Kong Gold & Silver Exchange Society, Chan appreciated the security and transparency provided by Ming Tak Finance.

Other Top Performers:

  • Wong Hou Yan (787%): Combined short-term trades with long-term trends, using Ming Tak Finances stable spread to effectively navigate the volatility of the gold market.
  • Wong Chun Man (687%): Employed a swing trading strategy to capitalize on price fluctuations, benefiting from Ming Tak Finances low spread and around-the-clock support.

Looking Ahead: The Final Round Approaches – Ming Tak Finance Continues to Offer Opportunities for Stable Profits

The success of the preliminary round has demonstrated Ming Tak Finances ability to provide a stable trading environment, highlighting the profit potential of gold trading. The winnersachievements were not only due to their personal strategies but also thanks to the platforms low spread, stable pricing, and transparent trading environment. As the final round nears, participants will face even more opportunities and challenges, reinforcing Ming Tak Finances commitment to offering dependable support to all traders.

Key Advantages of Ming Tak Finance Include:

  • 0.15 USD Ultra-Low Spread: Minimizes trading costs, maximizing profit potential.
  • Stable Pricing, No Price Manipulation: Ensures a fair trading environment, even during market fluctuations.
  • Fast Deposit and Withdrawal: Flexible fund management for seizing optimal trading opportunities.
  • 24/7 Trading Support: Professional customer service assistance available at any time.
  • Hong Kong Gold & Silver Exchange Society Membership & Hong Kong Customs Registration: Ensures fund security and regulatory support for traders.

Join Ming Tak Finance today to experience a professional gold trading platform, unlock market opportunities, and prepare for the final round!

Hashtag: #MingTakFinance #GoldTrading



The issuer is solely responsible for the content of this announcement.

About Ming Tak Finance: A Leading Gold Trading Platform with Low Spreads and Reliable Pricing

Ming Tak Finance is a Hong Kong Gold & Silver Exchange Society AA-class member (Member No. 194) and holds an A-class Precious Metals Trader license with Hong Kong Customs (Registration No. A-B-23-07-00744). As a leading platform for precious metals trading, we specialize in physical gold and margin trading services, committed to providing a stable, efficient, and transparent trading environment for all our clients.

With robust technological support and industry-leading transparency, Ming Tak Finance has built a strong reputation in precious metals trading, earning recognition such as the 2024 Excellence in Precious Metals Trading Platform Service Award from Capital Platform and the Best Precious Metals Trading Platform from iMoney Wealth Magazine.

Our professional team and innovative technology are dedicated to helping investors capitalize on market opportunities and achieve wealth growth. Whether you are an individual investor or an institutional client, Ming Tak Finance offers a reliable platform and excellent customer support to ensure a seamless and secure trading experience in the gold, silver, and other precious metals markets.

LONGi’s “Lighthouse Factory” was fully upgraded, HPBC 2.0 production line put into operation

XI’AN, China, Feb. 27, 2025 /PRNewswire/ — On February 25, LONGi held the “HPBC 2.0 ‘Lighthouse Factory’ Media Tour” at the Jiaxing base, which is the first time that the HPBC 2.0 production line has been opened to the public. Nearly 20 media were invited to visit the HPBC2.0 module production line to witness the whole manufacturing process of Hi-MO X10 modules.

"Lighthouse Factory " HPBC2.0 media tour on February 25
“Lighthouse Factory ” HPBC2.0 media tour on February 25

The HPBC 2.0 product was launched in May 2024, especially with the Hi-MO X10 module based on HPBC 2.0 launched in October 2024, the HPBC product has received an enthusiastic response in the market. In order to meet the needs of the market and customers, LONGi has fully launched the transformation and upgrading of its existing production lines from the second half of 2024. The “Lighthouse Factory” in Jiaxing base was chose to be the first batch of production bases to switch by its global leading advantages in intelligent manufacturing and digitalization.

According to LONGi’s capacity plan, HPBC2.0 production capacity will be expanded to 50GW by the end of 2025, and Jiaxing’s production capacity will remain above 20GW.

LONGi’s Jiaxing factory is the only “Lighthouse Factory” in the global PV industry so far. The “Lighthouse Factory” is known as “the world’s most advanced factory” and a model of “digital manufacturing” and “Industry 4.0”, representing the highest level of global intelligent manufacturing and digitalization. With the large-scale launch of Hi-MO X10 modules on the market, the Jiaxing factory has taken on the crucial task of ensuring a high-quality supply of products.

Xie Shundong, head of the second phase of Jiaxing manufacturing base, said at the event that LONGi has three bases in Jiaxing, which mainly producing HPBC 2.0 modules. By the end of 2025, the capacity of HPBC 2.0 modules will achieve 50GW, and the Jiaxing base will undertake at least 40% of it.

At present, the HPBC 2.0 production line of Jiaxing “Lighthouse Factory” has been fully upgraded, and the output is expected to achieve rapid growth by June.

At the event, LONGi also held a ceremony to witness the comprehensive upgrade and commissioning of the HPBC 2.0 production line.

Xie Shundong also said that at the beginning of this year, the “Lighthouse Factory” of LONGi Jiaxing base ushered in a comprehensive upgrade of the HPBC2.0 production line, with the production capacity increasing by at least 30% compared with the past, and the factory has implemented 24-hour uninterrupted production to ensure the market demand for BC products.

On February 14, LONGi celebrated an important milestone in its 25th anniversary. The warranty period of Hi-MO X10 has also been extended from 25 years to 30 years. Relying on the product life cycle quality management system, strict testing that exceeds IEC standards, and strict selection of materials, Hi-MO X10 has the confidence to promise a 30-year warranty cycle.

Nearly 20 media outlets witnessed the entire process of Hi-MO X10 manufacturing
Nearly 20 media outlets witnessed the entire process of Hi-MO X10 manufacturing

China’s economic resilience: new policies to buoy growth after achieving 2024 target

BEIJING, Feb. 27, 2025 /PRNewswire/ — A news report from Beijing Review:

Having reached its 2024 target, China is poised to continue promoting economic growth by exploring new drivers, analysts said.

China’s economy reached its annual growth target for 2024, with gross domestic product (GDP) expanding 5 percent year on year to reach 134.9084 trillion yuan ($18.5 trillion), according to data released by the National Bureau of Statistics (NBS) at a press conference on January 17.

In the third quarter of 2024, the Central Government introduced a series of incremental policies to encourage consumption and the creation of a more favorable business environment to boost the economy, which played a key role in achieving the full-year target, Kang Yi, Commissioner of the NBS, told the press conference.

“The supporting policies stabilized the stock and housing markets and boosted domestic demand. China’s economy made a robust rebound in 2024,” Xu Hongcai, Deputy Director of the Economic Policy Commission at the China Association of Policy Science, told Beijing Review. Xu noted that the quick ascent was aided by better-than-expected export performance and growing investment in hi-tech industries.

According to the statistics released by the General Administration of Customs of China, China’s import and export value reached 43.85 trillion yuan ($6 trillion) in 2024, a 5-percent year-on-year increase and a new historical high. Exports totaled 25.45 trillion yuan ($3.5 trillion), up 7.1 percent year on year.

In 2024, multiple sectors were promoting the integration of technological innovation and industrial innovation. Kang added that the Global Innovation Index 2024, released by the World Intellectual Property Organization, had ranked China 11th among the world’s most innovative economies, up one spot from the previous year.

The development of the country’s new-energy industries also achieved outstanding results in 2024. The greening of the energy industry is accelerating, and the proportion of clean energy generation is increasing. In 2024, hydropower, nuclear power, wind power and solar power accounted for 32.6 percent of power generation.

As of late December, the number of new-energy vehicles (NEVs) in use in China had reached 31.4 million, a 260-fold increase over the past decade, the Ministry of Public Security said on January 17, attributing the growth to improved charging infrastructure and more eco-friendly consumption options. NEVs refer to vehicles completely or mainly driven by new-energy sources, including battery electric vehicles, plug-in hybrid vehicles and fuel-cell vehicles.

Consumption continued to be a key driver. In late August last year, the government introduced a trade-in policy to encourage people to replace outdated household appliances and vehicles with newer, smarter and greener ones. This policy has had a strong, positive effect on the sales of new vehicles and home appliances. In 2024, China’s total auto sales reached 31.44 million, setting a new record, according to the China Association of Automobile Manufacturers. The trade-in policy gave a firm boost to auto sales.

Looking ahead, the government plans a stronger macroeconomic policy push for 2025, and has pledged to adopt a more proactive fiscal policy and a moderately loose monetary policy this year.

Contributing around 30 percent of global economic growth annually in recent years, China has been a major engine driving the world economy. The Chinese market continues to provide new opportunities for the world and the country has maintained its position as the world’s second largest importer for several years, with total import value reaching 18.39 trillion yuan ($2.5 trillion) in 2024.

However, it remains a developing country, with a big gap in per-capita GDP compared to developed nations, Kang said.

He cautioned that challenges, including weak consumer spending, difficulties facing businesses and employment pressure, remained. Geopolitical conflicts and rising protectionism have also added to the existing uncertainty.

In 2024, the national Producer Price Index (PPI) declined 2.2 percent year on year, less than the 3-percent drop in 2023. Xu said that the negative growth of PPI, a gauge of industrial product demand, was caused by weak demand in global and domestic markets, making it a key problem to address this year.

In 2024, fixed assets investment expanded 3.2 percent on a yearly basis. “But private investment saw negative year-on-year growth of 0.1 percent, suggesting that private enterprises lacked confidence,” Xu said.

At a symposium on private enterprises attended by prominent entrepreneurs including Huawei’s Ren Zhengfei and BYD’s Wang Chuanfu in Beijing on February 17, President Xi Jinping called for firming up confidence to promote the healthy and high-quality development of the private sector.

According to Xu, the authorities should channel more funds into hi-tech and green sectors, and improve the expectations of private and foreign-funded enterprises to expand investment.

Xu suggested further improving people’s incomes by boosting employment and the social security system cushioning the life of low-income groups.

“The government should also shore up rural consumption through enhancing logistics in remote areas and develop new growth drivers from emerging sectors such as the silver economy, which focuses on China’s elderly population,” he said.

First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer

SUZHOU, China, Feb. 27, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer.

Breast cancer is one of the most common malignant tumors among women worldwide and the most prevalent cancer in women in China. HER2-positive breast cancer is the most aggressive and highly malignant subtype. In recent years, the diagnosis and treatment of HER2-positive breast cancer has significantly improved. However, recurrent and metastatic breast cancer still has significant unmet clinical needs. JSKN003 is an anti-HER2 biparatopic ADC developed inhouse with Alphamab’s proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. The Phase III clinical studies of JSKN003 for HER2 low-expressing breast cancer (JSKN003-302) and platinum-resistant ovarian cancer (JSKN003-306) are currently progressing smoothly.

JSKN003-301 is a randomized, controlled, open-label, multicenter, Phase III clinical study aimed at evaluating the efficacy and safety of JSKN003 compared to emtansine (T-DM1) in the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have previously received trastuzumab or taxane-based therapies. The primary endpoint of the study is progression-free survival (PFS) as assessed by the Blinded Independent Review Committee (BIRC). The expedited progression of this study is anticipated to offer a treatment option with improved efficacy and safety for this patient population, further improving prognosis and quality of life.

About JSKN003

JSKN003 is an anti-HER2 biparatopic antibody-drug conjugate (ADC), which is developed inhouse with Alphamab’s proprietary Glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window.

Multiple clinical studies at various stages of JSKN003 are currently being conducted in China and Australia. Clinical research results have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer (PROC), or high HER2-expressing solid tumors.

In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the “Field”) in mainland China (excluding Hong Kong, Macau or Taiwan) (the “Territory”) and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003.

About Alphamab Oncology

Alphamab Oncology is a leading biopharmaceutical company committed to the development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification.

Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation (ADC), single domain antibody, and bispecific antibodies. Notably, Envafolimab, the world’s first subcutaneously injectable PD-L1 inhibitor, was approved by Chinese authorities in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are currently undergoing Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, Arrivent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive edge.